Cargando…

Serum IL-1β and IL-17 levels in patients with COPD: associations with clinical parameters

COPD is a chronic airway inflammatory disease characterized mainly by neutrophil airway infiltrations. Interleukin (IL)-1β and IL-17 are the key mediators of neutrophilic airway inflammation in COPD. This study was undertaken to evaluate the serum IL-1β and IL-17 levels and associations between thes...

Descripción completa

Detalles Bibliográficos
Autores principales: Zou, Yong, Chen, Xi, Liu, Jie, Zhou, Dong bo, Kuang, Xiao, Xiao, Jian, Yu, Qiao, Lu, Xiaoxiao, Li, Wei, Xie, Bin, Chen, Qiong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5413485/
https://www.ncbi.nlm.nih.gov/pubmed/28490868
http://dx.doi.org/10.2147/COPD.S131877
_version_ 1783233182421745664
author Zou, Yong
Chen, Xi
Liu, Jie
Zhou, Dong bo
Kuang, Xiao
Xiao, Jian
Yu, Qiao
Lu, Xiaoxiao
Li, Wei
Xie, Bin
Chen, Qiong
author_facet Zou, Yong
Chen, Xi
Liu, Jie
Zhou, Dong bo
Kuang, Xiao
Xiao, Jian
Yu, Qiao
Lu, Xiaoxiao
Li, Wei
Xie, Bin
Chen, Qiong
author_sort Zou, Yong
collection PubMed
description COPD is a chronic airway inflammatory disease characterized mainly by neutrophil airway infiltrations. Interleukin (IL)-1β and IL-17 are the key mediators of neutrophilic airway inflammation in COPD. This study was undertaken to evaluate the serum IL-1β and IL-17 levels and associations between these two key mediators with clinical parameters in COPD patients. Serum samples were collected from 60 COPD subjects during the acute exacerbation of COPD, 60 subjects with stable COPD and 40 healthy control subjects. Commercial enzyme-linked immunosorbent assay kits were used to measure the serum IL-1β and IL-17 concentrations. The association between serum IL-1β and IL-17 with FEV(1)% predicted, C-reactive protein, neutrophil percentage and smoking status (pack-years) was assessed in the COPD patients. We found that serum IL-1β and IL-17 levels in acute exacerbation of COPD subjects were significantly higher than that in stable COPD or control subjects and were positively correlated to serum C-reactive protein levels, neutrophil % and smoking status (pack-years) but negatively correlated with FEV(1)% predicted in COPD patients. More importantly, serum IL-1β levels were markedly positively associated with serum IL-17 levels in patients with COPD (P=0.741, P<0.001). In conclusion, elevated serum IL-1β and IL-17 levels may be used as a biomarker for indicating persistent neutrophilic airway inflammation and potential ongoing exacerbation of COPD.
format Online
Article
Text
id pubmed-5413485
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-54134852017-05-10 Serum IL-1β and IL-17 levels in patients with COPD: associations with clinical parameters Zou, Yong Chen, Xi Liu, Jie Zhou, Dong bo Kuang, Xiao Xiao, Jian Yu, Qiao Lu, Xiaoxiao Li, Wei Xie, Bin Chen, Qiong Int J Chron Obstruct Pulmon Dis Original Research COPD is a chronic airway inflammatory disease characterized mainly by neutrophil airway infiltrations. Interleukin (IL)-1β and IL-17 are the key mediators of neutrophilic airway inflammation in COPD. This study was undertaken to evaluate the serum IL-1β and IL-17 levels and associations between these two key mediators with clinical parameters in COPD patients. Serum samples were collected from 60 COPD subjects during the acute exacerbation of COPD, 60 subjects with stable COPD and 40 healthy control subjects. Commercial enzyme-linked immunosorbent assay kits were used to measure the serum IL-1β and IL-17 concentrations. The association between serum IL-1β and IL-17 with FEV(1)% predicted, C-reactive protein, neutrophil percentage and smoking status (pack-years) was assessed in the COPD patients. We found that serum IL-1β and IL-17 levels in acute exacerbation of COPD subjects were significantly higher than that in stable COPD or control subjects and were positively correlated to serum C-reactive protein levels, neutrophil % and smoking status (pack-years) but negatively correlated with FEV(1)% predicted in COPD patients. More importantly, serum IL-1β levels were markedly positively associated with serum IL-17 levels in patients with COPD (P=0.741, P<0.001). In conclusion, elevated serum IL-1β and IL-17 levels may be used as a biomarker for indicating persistent neutrophilic airway inflammation and potential ongoing exacerbation of COPD. Dove Medical Press 2017-04-24 /pmc/articles/PMC5413485/ /pubmed/28490868 http://dx.doi.org/10.2147/COPD.S131877 Text en © 2017 Zou et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Zou, Yong
Chen, Xi
Liu, Jie
Zhou, Dong bo
Kuang, Xiao
Xiao, Jian
Yu, Qiao
Lu, Xiaoxiao
Li, Wei
Xie, Bin
Chen, Qiong
Serum IL-1β and IL-17 levels in patients with COPD: associations with clinical parameters
title Serum IL-1β and IL-17 levels in patients with COPD: associations with clinical parameters
title_full Serum IL-1β and IL-17 levels in patients with COPD: associations with clinical parameters
title_fullStr Serum IL-1β and IL-17 levels in patients with COPD: associations with clinical parameters
title_full_unstemmed Serum IL-1β and IL-17 levels in patients with COPD: associations with clinical parameters
title_short Serum IL-1β and IL-17 levels in patients with COPD: associations with clinical parameters
title_sort serum il-1β and il-17 levels in patients with copd: associations with clinical parameters
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5413485/
https://www.ncbi.nlm.nih.gov/pubmed/28490868
http://dx.doi.org/10.2147/COPD.S131877
work_keys_str_mv AT zouyong serumil1bandil17levelsinpatientswithcopdassociationswithclinicalparameters
AT chenxi serumil1bandil17levelsinpatientswithcopdassociationswithclinicalparameters
AT liujie serumil1bandil17levelsinpatientswithcopdassociationswithclinicalparameters
AT zhoudongbo serumil1bandil17levelsinpatientswithcopdassociationswithclinicalparameters
AT kuangxiao serumil1bandil17levelsinpatientswithcopdassociationswithclinicalparameters
AT xiaojian serumil1bandil17levelsinpatientswithcopdassociationswithclinicalparameters
AT yuqiao serumil1bandil17levelsinpatientswithcopdassociationswithclinicalparameters
AT luxiaoxiao serumil1bandil17levelsinpatientswithcopdassociationswithclinicalparameters
AT liwei serumil1bandil17levelsinpatientswithcopdassociationswithclinicalparameters
AT xiebin serumil1bandil17levelsinpatientswithcopdassociationswithclinicalparameters
AT chenqiong serumil1bandil17levelsinpatientswithcopdassociationswithclinicalparameters